Dementia's Silent Rise: Are We Missing the Real Culprit?
The number of diagnoses for a specific type of dementia, known as LATE dementia (limbic-predominant age-related TDP-43 encephalopathy), is on the rise. This isn't necessarily because the disease is becoming more common, but rather because doctors are getting better at recognizing it. As awareness of LATE dementia grows, more cases are being identified, highlighting the complex landscape of cognitive decline beyond solely Alzheimer's disease. The New York Times delved deeper into this, exploring the various forms of dementia beyond the well-known Alzheimer's. This is crucial because different dementias have different underlying causes and may require different approaches to management and care.
But here's where it gets controversial... If LATE dementia is being underdiagnosed, could some people currently diagnosed with Alzheimer's actually have LATE? And what impact would this have on their treatment plans?
In other news, a clinical trial exploring a potential treatment for Alzheimer's disease has yielded mixed results. The ELAD trial investigated liraglutide (marketed as Saxenda and Victoza), a drug typically used for diabetes, as a way to improve brain function in people with mild to moderate Alzheimer's. While the study showed no significant difference in how the brain uses glucose (a key energy source) compared to a placebo, there was a small glimmer of hope: the drug seemed to have a positive impact on a secondary cognitive measure. This means patients showed some cognitive benefits, but the primary goal of improving brain metabolism wasn't met. The fact it had some impact is interesting and should not be dismissed, but it also means that liraglutide is not likely to be a major advancement as an Alzheimer's treatment.
Speaking of treatments, have you ever wondered if knowing you're at risk for Alzheimer's would change your behavior? A new study from the Wisconsin Registry for Alzheimer Prevention registry tracked adults who received amyloid PET scans (which can detect early signs of Alzheimer's) and found something surprising: those who learned they had elevated amyloid levels didn't significantly alter their health habits any more than those with normal results. This is a significant finding because it suggests that simply knowing your risk isn't always enough to motivate lifestyle changes. It begs the question: What would motivate people to take preventative action? More education? More personalized interventions? Stronger support systems?
On a lighter note, a neurobiologist has found a unique way to express their fascination with the brain: by creating stunning works of art featuring wooden neurons! These intricate sculptures transform the complex morphology of nerve cells into beautiful, tangible forms, offering a fresh perspective on the intricate beauty of the brain.
In the world of diagnostic tools, a meta-analysis revealed that a blood test measuring plasma phosphorylated tau 217 (p-tau217) can accurately identify individuals with Alzheimer's disease pathology even before they experience any noticeable cognitive symptoms. This is a major step forward in early detection, potentially allowing for earlier intervention and management. This test could be a game-changer for clinical trials, allowing researchers to target individuals at the very earliest stages of the disease.
Furthermore, research from the Whitehall II cohort study suggests that elevated levels of high-sensitivity cardiac troponin I (a marker of subtle heart damage) in middle age may predict an increased risk of dementia later in life. This highlights the interconnectedness of cardiovascular health and brain health, reinforcing the importance of maintaining a healthy heart for overall cognitive well-being.
And this is the part most people miss... It's not just about avoiding major heart attacks; even minor, subclinical heart damage could have long-term consequences for your brain.
Finally, there's some disappointing news from the world of multiple sclerosis (MS) research. Contineum Therapeutics announced that their investigational drug, PIPE-307, which aimed to repair nerve damage in MS by promoting myelin regrowth (remyelination), failed to meet its goals in a Phase II clinical trial. Myelin is a protective sheath around nerve fibers, and its damage is a hallmark of MS. The VISTA trial results indicate that the drug did not significantly improve either the primary or secondary measures of efficacy. This setback underscores the challenges of developing effective remyelination therapies for MS.
What are your thoughts on these findings? Does the rise in LATE dementia diagnoses change how we should approach dementia research and treatment? And what do you think it will take to motivate people to take proactive steps for their brain health?
